Finerenone Placebo

Pipeline

Status by Indication[2][1]

Competition

Competitive Landscape

7 competitors in Diabetic Kidney Disease

#DrugCompanyPhaseTrials

1

Kerendia

Bayer

Approved

22

Jardiance

Boehringer Ingelheim

Approved

23

Mazdutide

Eli Lilly

Phase 3

14

Angiotensin Receptor Blocker

NNational University of Ireland, Galway, Ireland

Phase 3

15

Finerenone Placebo

Bayer

Phase 3

16

AP303 150μg

AAlebund Pharmaceuticals

Phase 1

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Albuminuria1 trial

Study on the Efficacy and Safety of Initial Combination of Finerenone and Semaglutide in Non-diabetic Adult Patients With Obesity Complicated by Chronic Kidney Disease With Albuminuria

Not yet recruiting·PPeking University People's Hospital·Preclinical·NCT07849348·266 enrolled

Diabetic Kidney Disease1 trial

QUAdruple Therapy With RASi, Empagliflozin, Finerenone, and Mazdutide in Type 2 Diabetes and Early Treatment of Nephropathy(QUARTET-DKD)

Not yet recruiting·HHuijie Zhang·Approved·NCT07775846·820 enrolled

Acute Heart Failure1 trial

Efficacy and Safety With Early Treatment of Finerenone in Hospitalized Patients With Heart Failure

Recruiting·JJuntendo University·Approved·NCT07397650·550 enrolled

Type 2 Diabetes Mellitus1 trial

A Parallel-group Treatment, Phase 2, Double-blind, Three-arm Study to Assess Efficacy and Safety of Finerenone Plus Empagliflozin Compared With Either Finerenone or Empagliflozin Alone in Participants With Chronic Kidney Disease and Type 2 Diabetes.

Completed·Bayer·Phase 2·NCT05254002·1,664 enrolled

Details

Drug Info

Related News